<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Metastatic well-differentiated gastroenteropancreatic neuroendocrine tumors: Presentation, prognosis, imaging, and biochemical monitoring</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Metastatic well-differentiated gastroenteropancreatic neuroendocrine tumors: Presentation, prognosis, imaging, and biochemical monitoring</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Metastatic well-differentiated gastroenteropancreatic neuroendocrine tumors: Presentation, prognosis, imaging, and biochemical monitoring</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jennifer Ang Chan, MD, MPH</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Matthew Kulke, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard M Goldberg, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sonali M Shah, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 15, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Neuroendocrine cells are distributed widely throughout the body, and neuroendocrine neoplasms can arise at many sites. While there are differences in terminology and grading for tumors arising at different sites, all commonly used classification systems reflect a basic separation between more indolent, well-differentiated neuroendocrine tumors (NETs; which in the past, were referred to as carcinoid tumors when arising in the digestive system [now termed gastrointestinal NETs], or pancreatic islet cell tumors [pancreatic NETs]) and far more aggressive, poorly differentiated neoplasms that behave clinically more like small cell carcinoma of the lung (termed neuroendocrine carcinomas). (See  <a class="medical medical_review" href="/d/html/98796.html" rel="external">"High-grade gastroenteropancreatic neuroendocrine neoplasms"</a> and  <a class="medical medical_review" href="/d/html/4628.html" rel="external">"Pathobiology and staging of small cell carcinoma of the lung"</a>.)</p><p>The clinical presentation, prognosis, radiographic imaging, and tumor marker evaluation of patients with well-differentiated NETs arising in the digestive system are discussed in this topic review. Pathology and nomenclature of gastroenteropancreatic NETs, treatment options for advanced or metastatic NETs, as well as issues relating to the presentation, localization, and treatment of early stage gastrointestinal NETs and pancreatic NETs are presented elsewhere, as are small cell lung cancer, high-grade gastroenteropancreatic neuroendocrine carcinoma, and neuroendocrine carcinoma of unknown primary site.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/14247.html" rel="external">"Pathology, classification, and grading of neuroendocrine neoplasms arising in the digestive system"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/16105.html" rel="external">"Metastatic gastroenteropancreatic neuroendocrine tumors: Local options to control tumor growth and symptoms of hormone hypersecretion"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/2613.html" rel="external">"Clinical characteristics of well-differentiated neuroendocrine (carcinoid) tumors arising in the gastrointestinal and genitourinary tracts"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/2622.html" rel="external">"Diagnosis of carcinoid syndrome and tumor localization"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/2615.html" rel="external">"Staging, treatment, and post-treatment surveillance of non-metastatic, well-differentiated gastrointestinal tract neuroendocrine (carcinoid) tumors"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/4883.html" rel="external">"Lung neuroendocrine (carcinoid) tumors: Epidemiology, risk factors, classification, histology, diagnosis, and staging"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/2612.html" rel="external">"Classification, epidemiology, clinical presentation, localization, and staging of pancreatic neuroendocrine neoplasms"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/2187.html" rel="external">"Insulinoma"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/2611.html" rel="external">"Glucagonoma and the glucagonoma syndrome"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/2608.html" rel="external">"Somatostatinoma: Clinical manifestations, diagnosis, and management"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/2610.html" rel="external">"VIPoma: Clinical manifestations, diagnosis, and management"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/4876.html" rel="external">"Neuroendocrine neoplasms of unknown primary site"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/98796.html" rel="external">"High-grade gastroenteropancreatic neuroendocrine neoplasms"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/4628.html" rel="external">"Pathobiology and staging of small cell carcinoma of the lung"</a>.)</p><p></p><p class="headingAnchor" id="H262522852"><span class="h1">CLASSIFICATION AND NOMENCLATURE</span><span class="headingEndMark"> — </span>The World Health Organization (WHO) classification of neuroendocrine neoplasms arising in the digestive system separates these tumors into two broad categories  (<a class="graphic graphic_table graphicRef122325" href="/d/graphic/122325.html" rel="external">table 1</a>) [<a href="#rid1">1</a>] (see  <a class="medical medical_review" href="/d/html/14247.html" rel="external">"Pathology, classification, and grading of neuroendocrine neoplasms arising in the digestive system", section on 'Pathology, tumor classification, and nomenclature'</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Well-differentiated NETs, which show a solid, trabecular, gyriform, or glandular pattern, with fairly uniform nuclei, salt-and-pepper chromatin, and finely granular cytoplasm. They are divided into low-grade (G1), intermediate-grade (G2), and high-grade (G3) subtypes based on proliferative rate.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Poorly differentiated neuroendocrine carcinomas, which are G3 carcinomas that resemble small cell or large cell neuroendocrine carcinoma of the lung  (<a class="graphic graphic_picture graphicRef74630" href="/d/graphic/74630.html" rel="external">picture 1</a>) [<a href="#rid2">2</a>]. (See  <a class="medical medical_review" href="/d/html/98796.html" rel="external">"High-grade gastroenteropancreatic neuroendocrine neoplasms"</a> and  <a class="medical medical_review" href="/d/html/4603.html" rel="external">"Pathology of lung malignancies", section on 'Neuroendocrine tumors'</a>.)</p><p></p><p>Poorly differentiated neuroendocrine carcinomas are often associated with a rapid clinical course; as such, their clinical behavior is similar to that of small cell carcinoma of the lung, and they are treated similarly with platinum-based chemotherapy. (See  <a class="medical medical_review" href="/d/html/98796.html" rel="external">"High-grade gastroenteropancreatic neuroendocrine neoplasms"</a>.)</p><p>By contrast, most well-differentiated gastroenteropancreatic NETs generally have a much better prognosis. Even in the presence of liver metastases, some patients may survive for many years. However, these tumors are not a homogeneous group, but instead display a spectrum of aggressiveness. Within the subgroup of well-differentiated NETs, morphology alone cannot predict tumor behavior. Proliferative rate, as assessed by mitotic count and/or Ki-67 labeling index, is of prognostic significance, independent of tumor stage [<a href="#rid3">3,4</a>].</p><p>There is a small subset of patients with NETs that appear histologically well differentiated, with fewer than 20 mitoses per 10 high-power fields (G2 by mitotic count), but are associated with high Ki-67 proliferation indices (&gt;20 percent) that fall into the G3 range. The clinical behavior of these grade-discordant tumors is somewhat worse than grade-concordant well-differentiated G2 NETs but is better than that of bona fide poorly differentiated neuroendocrine carcinomas. (See  <a class="medical medical_review" href="/d/html/14247.html" rel="external">"Pathology, classification, and grading of neuroendocrine neoplasms arising in the digestive system", section on 'High-grade, well-differentiated neoplasms'</a>.)</p><p>Digestive tract NETs can also be defined by their functional, or hormone-secreting, status. Functioning NETs are characterized by the presence of clinical symptoms due to excess hormone secretion by the tumor. Functioning (hormone-secreting) pancreatic NETs are classified according to the predominant hormone they secrete and the resulting clinical syndrome (eg, insulinoma, gastrinoma, glucagonoma, VIPoma, somatostatinoma). Functioning gastrointestinal NETs (ie, those associated with the carcinoid syndrome) are not classified differently than nonfunctioning tumors. Although functionality may impact prognosis (eg, insulinomas are generally indolent tumors), the biologic behavior of most functioning NETs is defined by the grade and stage of the tumor, just as it is in nonfunctioning tumors. The vast majority of functioning tumors are well differentiated. (See  <a class="medical medical_review" href="/d/html/2187.html" rel="external">"Insulinoma"</a> and  <a class="medical medical_review" href="/d/html/2627.html" rel="external">"Zollinger-Ellison syndrome (gastrinoma): Clinical manifestations and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/2611.html" rel="external">"Glucagonoma and the glucagonoma syndrome"</a> and  <a class="medical medical_review" href="/d/html/2610.html" rel="external">"VIPoma: Clinical manifestations, diagnosis, and management"</a> and  <a class="medical medical_review" href="/d/html/2608.html" rel="external">"Somatostatinoma: Clinical manifestations, diagnosis, and management"</a> and  <a class="medical medical_review" href="/d/html/2614.html" rel="external">"Clinical features of carcinoid syndrome"</a> and  <a class="medical medical_review" href="/d/html/2622.html" rel="external">"Diagnosis of carcinoid syndrome and tumor localization"</a> and  <a class="medical medical_review" href="/d/html/14247.html" rel="external">"Pathology, classification, and grading of neuroendocrine neoplasms arising in the digestive system", section on 'Functionality and nomenclature'</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">CLINICAL PRESENTATION</span><span class="headingEndMark"> — </span>The clinical course of patients with metastatic well-differentiated gastroenteropancreatic NET is highly variable. Some untreated patients with indolent tumors remain symptom free for years, while others have symptomatic disease, either from tumor bulk or peptide hormone hypersecretion. Patients with functioning pancreatic NETs typically have symptoms caused by the specific type of hormone being produced by the tumor. (See  <a class="medical medical_review" href="/d/html/2611.html" rel="external">"Glucagonoma and the glucagonoma syndrome", section on 'Clinical features'</a> and  <a class="medical medical_review" href="/d/html/2187.html" rel="external">"Insulinoma", section on 'Symptoms and misdiagnosis'</a> and  <a class="medical medical_review" href="/d/html/2608.html" rel="external">"Somatostatinoma: Clinical manifestations, diagnosis, and management", section on 'Clinical manifestations'</a> and  <a class="medical medical_review" href="/d/html/2610.html" rel="external">"VIPoma: Clinical manifestations, diagnosis, and management", section on 'Clinical features'</a>.)</p><p>For patients with metastatic gastrointestinal NETs, the secretion of serotonin and other vasoactive substances causes carcinoid syndrome, which is manifested by episodic flushing, wheezing, diarrhea, and eventual right-sided valvular heart disease [<a href="#rid5">5</a>]. The carcinoid syndrome is most commonly seen with midgut NETs (small intestine, appendix, proximal large bowel), almost exclusively in the setting of metastatic (usually liver) disease. It is rare with foregut (gastric, bronchial) and hindgut (distal colon, rectum, genitourinary) NETs. In addition, foregut NETs can be associated with an atypical variant of carcinoid syndrome. Patients with extraintestinal (eg, ovarian and bronchial) NETs can develop carcinoid syndrome in the absence of liver metastases  (<a class="graphic graphic_table graphicRef56015" href="/d/graphic/56015.html" rel="external">table 2</a>). (See  <a class="medical medical_review" href="/d/html/2614.html" rel="external">"Clinical features of carcinoid syndrome"</a> and  <a class="medical medical_review" href="/d/html/2613.html" rel="external">"Clinical characteristics of well-differentiated neuroendocrine (carcinoid) tumors arising in the gastrointestinal and genitourinary tracts"</a> and  <a class="medical medical_review" href="/d/html/2622.html" rel="external">"Diagnosis of carcinoid syndrome and tumor localization"</a>.)</p><p class="headingAnchor" id="H262522922"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>Even when advanced, survival times for patients with well-differentiated gastroenteropancreatic NETs are generally better than those for patients with other malignancies [<a href="#rid6">6</a>], although prognosis can be highly variable. A major factor impacting overall survival is primary tumor site [<a href="#rid6">6</a>]. In an analysis of cases in the National Cancer Institute (NCI) Surveillance, Epidemiology, and End Results (SEER) database of NETs diagnosed between 2000 and 2012, the median survival for patients with distant metastases from grade 1 to 2 pancreatic NETs was 50 months. For patients with distant metastases from grade 1 to 2 small intestinal NETs, median survival was 103 months; by contrast, it was only 14 months for patients with colonic primary tumors [<a href="#rid7">7</a>].</p><p>Another major prognostic factor is histologic grade, which is assigned based on the mitotic rate or Ki-67 labeling index [<a href="#rid7">7,8</a>]. As an example, in the SEER database analysis, patients with a grade 1 or 2 appendiceal NET, or a grade 1 rectal NET had a median survival &gt;30 years. By contrast, patients with grade 3 neuroendocrine carcinoma had poor overall survival irrespective of primary tumor site, ranging from 30 to 33 months for small intestine and appendix, respectively, to 8 months for cecum and colon [<a href="#rid7">7</a>]. (See  <a class="medical medical_review" href="/d/html/14247.html" rel="external">"Pathology, classification, and grading of neuroendocrine neoplasms arising in the digestive system", section on 'Staging system'</a>.)</p><p>Other prognostic factors in patients with metastatic disease include disease burden, the presence of distant extrahepatic metastases, race, and older age [<a href="#rid7">7,9</a>].</p><p class="headingAnchor" id="H3"><span class="h1">IMAGING</span><span class="headingEndMark"> — </span>The predominant site of metastatic spread well-differentiated NETs is the liver  (<a class="graphic graphic_picture graphicRef61729" href="/d/graphic/61729.html" rel="external">picture 2</a>). Liver function tests are an unreliable indicator of tumor involvement; the serum total bilirubin and/or alkaline phosphatase are frequently normal despite extensive liver involvement. Imaging is therefore an important aspect of monitoring patients with advanced gastroenteropancreatic NETs for evidence of disease progression or treatment response.</p><p class="headingAnchor" id="H21668993"><span class="h2">Well-differentiated neuroendocrine tumors</span></p><p class="headingAnchor" id="H262522974"><span class="h3">Cross-sectional imaging</span><span class="headingEndMark"> — </span>For patients with advanced gastroenteropancreatic NETs, cross-sectional anatomic imaging is the standard approach to monitoring patients and is generally performed with either multiphasic computed tomography (CT) or magnetic resonance imaging (MRI). Triphasic helical CT of the abdomen and pelvis is recommended to image metastatic gastrointestinal and pancreatic NETs [<a href="#rid10">10,11</a>]. These tumors are highly vascular and may appear isodense with the liver during certain contrast phases  (<a class="graphic graphic_diagnosticimage graphicRef52935" href="/d/graphic/52935.html" rel="external">image 1</a>). They generally enhance most intensely with intravenous contrast during the early arterial phases of imaging, with washout during the delayed portal venous phase.</p><p>MRI is a reasonable alternative, as lesions can be visualized without contrast in T1 and T2-weighted sequences, reducing the variability sometimes seen with CT-based imaging results  (<a class="graphic graphic_diagnosticimage graphicRef59487" href="/d/graphic/59487.html" rel="external">image 2</a> and <a class="graphic graphic_diagnosticimage graphicRef72303" href="/d/graphic/72303.html" rel="external">image 3</a>). In one study, MRI detected significantly more metastases than either planar somatostatin receptor scintigraphy (SRS) using indium-111 (111-In) pentetreotide (OctreoScan) or CT (sensitivity rates for MRI, planar SRS, and CT were 95, 79, and 49 percent, respectively) [<a href="#rid12">12</a>]. As a result of this greater sensitivity for liver metastases, some clinicians prefer MRI over CT. Consensus-based guidelines from the European Neuroendocrine Tumor Society (ENETS) state that MRI should be considered superior to CT for the detection and follow-up of liver metastases from NETs [<a href="#rid13">13,14</a>].</p><p class="headingAnchor" id="H5"><span class="h3">Somatostatin receptor-based imaging techniques</span><span class="headingEndMark"> — </span>Over 90 percent of gastroenteropancreatic NETs, including nonfunctioning NETs (with the exception of insulinomas), have high concentrations of somatostatin receptors and can be imaged using a radiolabeled form of the somatostatin analog <a class="drug drug_general" data-topicid="9714" href="/d/drug information/9714.html" rel="external">octreotide</a> (111-In pentetreotide). More recently, a number of positron emission tomography (PET)-based, somatostatin receptor-based imaging techniques have also been evaluated. One of these radionuclides, <a class="drug drug_general" data-topicid="108440" href="/d/drug information/108440.html" rel="external">gallium Ga-68 DOTATATE</a> (Ga-68 DOTATATE), was approved by the US Food and Drug Administration (FDA) for routine use in patients with NETs in June 2016 [<a href="#rid15">15</a>]. The higher sensitivity of Ga-68 DOTATATE suggests that this is the preferred option for most clinical scenarios, particularly in patients with smaller tumor volume or an occult primary tumor [<a href="#rid16">16</a>]. Two other radionuclides, gallium Ga-68 DOTATOC (Ga-68 DOTATOC) and <a class="drug drug_general" data-topicid="129471" href="/d/drug information/129471.html" rel="external">copper Cu-64 DOTATATE</a> (Cu-64 DOTATATE), were subsequently approved.</p><p class="headingAnchor" id="H1661884995"><span class="h4">Clinical use</span><span class="headingEndMark"> — </span>Baseline imaging using one of the somatostatin receptor-based imaging techniques is generally recommended in patients with advanced NETs, both as an adjunct to routine cross-sectional imaging and because evidence of somatostatin receptor expression (based on a positive scan) can be predictive of a clinical response to therapy with somatostatin analogs, such as <a class="drug drug_general" data-topicid="9714" href="/d/drug information/9714.html" rel="external">octreotide</a> and <a class="drug drug_general" data-topicid="10184" href="/d/drug information/10184.html" rel="external">lanreotide</a> [<a href="#rid17">17</a>], as well as peptide receptor radioligand therapy. (See  <a class="medical medical_review" href="/d/html/16901.html" rel="external">"Metastatic well-differentiated gastrointestinal neuroendocrine (carcinoid) tumors: Systemic therapy options to control tumor growth", section on 'Somatostatin analogs'</a> and  <a class="medical medical_review" href="/d/html/90664.html" rel="external">"Metastatic well-differentiated pancreatic neuroendocrine tumors: Systemic therapy options to control tumor growth and symptoms of hormone hypersecretion", section on 'Somatostatin analogs'</a> and  <a class="medical medical_review" href="/d/html/90664.html" rel="external">"Metastatic well-differentiated pancreatic neuroendocrine tumors: Systemic therapy options to control tumor growth and symptoms of hormone hypersecretion", section on 'Peptide receptor radioligand therapy'</a> and  <a class="medical medical_review" href="/d/html/16901.html" rel="external">"Metastatic well-differentiated gastrointestinal neuroendocrine (carcinoid) tumors: Systemic therapy options to control tumor growth", section on 'Somatostatin receptor-expressing tumors'</a>.)</p><p>Whether either of these techniques should be used to assess tumor response or progression in patients with advanced disease is unclear, and this has not yet been formally studied [<a href="#rid16">16</a>]. These imaging techniques rely in part on the assessment of somatostatin receptor density, rather than direct measurements of tumor volume. Using somatostatin receptor-based techniques may, in theory, not always correlate with disease progression or response to therapy, and further studies are needed to assess the utility of these technologies (including <a class="drug drug_general" data-topicid="108440" href="/d/drug information/108440.html" rel="external">Ga-68 DOTATATE</a>, Ga-68 DOTATOC, and Cu-64 DOTATATE) in this setting.</p><p>For patients treated with somatostatin analogs, it has generally been recommended that therapy with short-acting analogs be discontinued for 24 hours before somatostatin receptor-based imaging, with treatment resumed the day after, when clinically feasible [<a href="#rid18">18</a>]. For patients receiving long-acting preparations (Sandostatin LAR, <a class="drug drug_general" data-topicid="10184" href="/d/drug information/10184.html" rel="external">lanreotide</a>) the recommendation has been to allow a wash-out period of four weeks before imaging or to image just prior to dosing with long-acting somatostatin analogs. However, these recommendations preceded the availability of more sensitive imaging techniques using PET. Several studies have found that treatment with long-acting somatostatin analogs (lanreotide, <a class="drug drug_general" data-topicid="9714" href="/d/drug information/9714.html" rel="external">octreotide</a>) did not alter <a class="drug drug_general" data-topicid="108440" href="/d/drug information/108440.html" rel="external">Ga-68 DOTATATE</a> uptake into tumors or affect imaging results, suggesting that the recommended dose separation of these agents may not be needed in this setting [<a href="#rid19">19-21</a>]. We no longer recommend holding the somatostatin analog for a period of time prior to PET imaging.</p><p class="headingAnchor" id="H1107628827"><span class="h4">Clinical studies</span><span class="headingEndMark"> — </span>Scanning using 111-In pentetreotide has been widely available and has been commonly used to perform whole-body somatostatin receptor-based imaging in patients with NETs [<a href="#rid22">22-24</a>].</p><p>However, several PET tracers for functional imaging have emerged (<a class="drug drug_general" data-topicid="108440" href="/d/drug information/108440.html" rel="external">Ga-68 DOTATATE</a>, Ga-68 DOTATOC, Cu-64 DOTATATE, 18-F-dihydroxy-phenyl-alanine [18F-DOPA], and 11-C-5-hydroxytryptophan [11-C-5-HTP]), which in combination with high-resolution PET and integrated CT, improve the detection and staging of NETs. Novel PET modalities such as Ga-68 DOTATATE, Ga-68 DOTATOC and Cu-64 DOTATATE PET offer higher spatial resolution than conventional 111-In pentetreotide imaging and are more sensitive for detection of small lesions  (<a class="graphic graphic_diagnosticimage graphicRef81388" href="/d/graphic/81388.html" rel="external">image 4</a>) [<a href="#rid25">25-34</a>].</p><p><a class="drug drug_general" data-topicid="108440" href="/d/drug information/108440.html" rel="external">Ga-68 DOTATATE</a> is a positron-emitting analog of somatostatin that works by binding to these receptors; its highest affinity is for subtype 2 receptors (sstr2). The higher sensitivity of Ga-68 DOTATATE PET for the detection of gastroenteropancreatic NETs was best shown in a prospective study in which 131 patients with a known or suspected gastroenteropancreatic NET underwent conventional anatomic imaging with CT and/or MRI, 111-In pentetreotide SPECT/CT imaging, and Ga-68 DOTATATE PET/CT [<a href="#rid25">25</a>]. The following findings were noted:</p><p class="bulletIndent1"><span class="glyph">●</span>When all of the lesions demonstrated by any of the imaging studies were used as the imaging denominator, Ga-68-DOTATATE PET/CT imaging detected significantly more (95 percent, 95% CI 92.4-96.8) than did anatomic imaging (45 percent, 95% CI 37.9-52.9 percent) or 111-In pentetreotide SPECT/CT (30.9 percent, 95% CI 25.0-37.5 percent). Overall, 422 of the total 891 lesions were detected by 68-Ga-DOTATATE PET/CT and missed both by 111-In pentetreotide SPECT/CT and anatomic imaging.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Of the 14 patients with an unknown primary tumor, four were identified using <a class="drug drug_general" data-topicid="108440" href="/d/drug information/108440.html" rel="external">Ga-68 DOTATATE</a> (none of which were seen with 111-In pentetreotide and two of which were not seen on cross sectional imaging). (See  <a class="medical medical_review" href="/d/html/4876.html" rel="external">"Neuroendocrine neoplasms of unknown primary site"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The 25 patients who underwent surgery had 113 lesions that were histologically proven to be gastroenteropancreatic NETs (37 primary tumors, 69 lymph nodes, and 7 distant metastases). On a per-lesion analysis, <a class="drug drug_general" data-topicid="108440" href="/d/drug information/108440.html" rel="external">Ga-68 DOTATATE</a> had the highest true positive rate (72 of 113 [64 percent] versus 25 of 113 [22 percent] for 111-In pentetreotide and 44 of 113 [39 percent] for anatomic imaging). All 38 lesions that were not detected by any imaging study represented lymph node metastases.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The addition of Ga-68-DOTATATE scanning to cross-sectional imaging and 111-In pentetreotide resulted in a clinically significant change in management in 43 of 131 patients (33 percent).</p><p></p><p>A newer PET radiotracer, Ga-68 DOTATOC, appears to have comparable diagnostic accuracy to <a class="drug drug_general" data-topicid="108440" href="/d/drug information/108440.html" rel="external">Ga-68 DOTATATE</a> for the detection of neuroendocrine neoplasms that express somatostatin receptors [<a href="#rid35">35</a>]. Although FDA approved in the United States in 2019 [<a href="#rid36">36</a>], it is not yet commercially available. </p><p>A third PET radiotracer, Cu-64 DOTATATE, appears also to have comparable diagnostic accuracy to <a class="drug drug_general" data-topicid="108440" href="/d/drug information/108440.html" rel="external">Ga-68 DOTATATE</a> [<a href="#rid37">37</a>] and was approved in the United States in September 2020.</p><p>Whole-body imaging using radiolabeled somatostatin analogs such as <a class="drug drug_general" data-topicid="108440" href="/d/drug information/108440.html" rel="external">Ga-68 DOTATATE</a> and DOTATOC, or Cu-64 DOTATATE may unexpectedly reveal other somatostatin receptor-expressing tumor types, including meningiomas [<a href="#rid38">38</a>]. The differential diagnosis includes a wide range of neoplastic and nonneoplastic entities, including metastatic NET  (<a class="graphic graphic_table graphicRef109028" href="/d/graphic/109028.html" rel="external">table 3</a>). (See  <a class="medical medical_review" href="/d/html/5220.html" rel="external">"Epidemiology, pathology, clinical features, and diagnosis of meningioma", section on 'Diagnostic evaluation'</a> and  <a class="medical medical_review" href="/d/html/5230.html" rel="external">"Management of known or presumed benign (WHO grade 1) meningioma", section on 'Small, asymptomatic tumors'</a>.)</p><p class="headingAnchor" id="H2459452014"><span class="h2">Poorly differentiated neuroendocrine tumors</span><span class="headingEndMark"> — </span>Imaging for high-grade poorly differentiated neuroendocrine carcinomas arising in the gastrointestinal tract is discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/98796.html" rel="external">"High-grade gastroenteropancreatic neuroendocrine neoplasms", section on 'Diagnosis and staging'</a>.)</p><p class="headingAnchor" id="H8"><span class="h1">BIOCHEMICAL MONITORING</span></p><p class="headingAnchor" id="H1819989413"><span class="h2">Hormonal biomarkers</span></p><p class="headingAnchor" id="H9"><span class="h3">Urinary 5-HIAA</span><span class="headingEndMark"> — </span>Elevated urinary levels of 5-hydroxyindoleacetic acid (5-HIAA) are highly specific for serotonin-producing NETs (ie, those arising in the midgut), but they are not particularly sensitive. In one study, only 73 percent of patients with metastatic NETs had elevated levels [<a href="#rid39">39</a>]. Furthermore, 5-HIAA levels are generally most useful in patients with primary midgut NETs. Foregut and hindgut NETs only rarely secrete serotonin; they lack the enzyme DOPA decarboxylase and cannot convert 5-hydroxytryptophan to serotonin and, therefore, to 5-HIAA  (<a class="graphic graphic_figure graphicRef51368" href="/d/graphic/51368.html" rel="external">figure 1</a>).</p><p>Clinical utility can also be limited by false positives. The normal rate of 5-HIAA excretion ranges from 2 to 8 mg (10 to 42 micromol) per day. Values of up to 30 mg (157 micromol) per day may be found in patients with malabsorption syndromes (eg, celiac disease), and following ingestion of large amounts of tryptophan/serotonin-rich foods; use of certain drugs also interferes with assay of urinary 5-HIAA  (<a class="graphic graphic_table graphicRef79968" href="/d/graphic/79968.html" rel="external">table 4</a>). Although many patients with advanced well-differentiated midgut NETs have values above 100 mg (523 micromol) per day, some have more modest elevations. In one study, urinary 5-HIAA excretion in patients with carcinoid syndrome ranged from 99 to 2070 mg (518 to 10826 micromol) per day [<a href="#rid40">40</a>]. Lower but still elevated values were seen in patients with metastatic NETs without carcinoid syndrome (50 to 260 mg [262 to 1360 micromol] per day).</p><p>Urinary 5-HIAA is the most sensitive test for establishing the diagnosis of carcinoid syndrome. (See  <a class="medical medical_review" href="/d/html/2622.html" rel="external">"Diagnosis of carcinoid syndrome and tumor localization", section on 'Biochemical testing for carcinoid syndrome'</a>.)</p><p>For patients with advanced disease, serial measurements of 24-hour urine 5-HIAA do not correlate with symptomatic benefit from various treatments [<a href="#rid41">41</a>].</p><p class="headingAnchor" id="H11716132"><span class="h3">Functioning pancreatic neuroendocrine tumors</span><span class="headingEndMark"> — </span>While they are specific for the individual hormonal syndrome, the hormones produced by functioning pancreatic NETs (ie, insulin, glucagon, somatostatin, VIP) may not be easily measurable. Assessment of specific hormone levels should be performed based on patient symptoms and suspicion for a functional NET. (See  <a class="medical medical_review" href="/d/html/2187.html" rel="external">"Insulinoma", section on 'Diagnosis and staging'</a> and  <a class="medical medical_review" href="/d/html/2611.html" rel="external">"Glucagonoma and the glucagonoma syndrome", section on 'Serum glucagon'</a> and  <a class="medical medical_review" href="/d/html/2627.html" rel="external">"Zollinger-Ellison syndrome (gastrinoma): Clinical manifestations and diagnosis", section on 'Serum gastrin concentration'</a> and  <a class="medical medical_review" href="/d/html/2610.html" rel="external">"VIPoma: Clinical manifestations, diagnosis, and management", section on 'Diagnosis'</a> and  <a class="medical medical_review" href="/d/html/2608.html" rel="external">"Somatostatinoma: Clinical manifestations, diagnosis, and management", section on 'Diagnosis'</a>.)</p><p class="headingAnchor" id="H1744213147"><span class="h2">Nonhormonal biomarkers</span></p><p class="headingAnchor" id="H10"><span class="h3">Chromogranin A</span><span class="headingEndMark"> — </span>Chromogranin A (CgA) is a 49-kD protein that is contained in the neurosecretory vesicles of NET cells and is detectable in the plasma of patients with a range of neuroendocrine neoplasms, including nonfunctioning pancreatic NETs. Because it does not rely on serotonin secretion, serum CgA is a more sensitive and broadly applicable tumor marker for NETs than is urinary 5HIAA, but it is less specific  (<a class="graphic graphic_table graphicRef73287" href="/d/graphic/73287.html" rel="external">table 5</a>). (See  <a class="medical medical_review" href="/d/html/130551.html" rel="external">"Overview of tumor biomarkers in gastroenteropancreatic neuroendocrine tumors", section on 'Chromogranin A (CgA)'</a>.)</p><p>Among the clinical scenarios where CgA may be used includes patients with foregut and rectal NETs (in whom urinary 5HIAA levels are less likely to be elevated), as well as in patients with pancreatic NETs, in whom CgA is more often elevated than it is with gastrointestinal tract NETs [<a href="#rid42">42-52</a>]. Levels are higher in patients with diffuse metastases than with localized disease or isolated hepatic involvement [<a href="#rid46">46,52</a>]. (See  <a class="medical medical_review" href="/d/html/2613.html" rel="external">"Clinical characteristics of well-differentiated neuroendocrine (carcinoid) tumors arising in the gastrointestinal and genitourinary tracts", section on 'Foregut tumors'</a> and  <a class="medical medical_review" href="/d/html/2613.html" rel="external">"Clinical characteristics of well-differentiated neuroendocrine (carcinoid) tumors arising in the gastrointestinal and genitourinary tracts", section on 'Hindgut tumors'</a>.)</p><p>Plasma CgA levels have been shown to correlate with treatment response and may also have prognostic value. Elevated CgA levels have been associated with shorter overall survival times in several studies [<a href="#rid3">3,53-56</a>]. However, the utility of CgA as a marker of prognosis has been limited by wide variability in CgA ranges in the setting of metastatic disease, as well as variability in CgA assays in the United States and Europe. Caution is also needed when using serum CgA as a marker of disease activity in patients treated with somatostatin analogs. These agents significantly reduce plasma CgA levels, a change that may be more reflective of changes in hormonal synthesis and release from tumor cells than an actual reduction in tumor mass [<a href="#rid45">45</a>]. Finally, CgA is not recommended as a diagnostic marker for NETs, as it can be elevated in a number of unrelated conditions. These conditions include use of proton pump inhibitors, renal insufficiency, and hepatic insufficiency. For patients who are receiving treatment with a proton pump inhibitor, the drug should be stopped or replaced with an H2 receptor blocker if possible in order to obtain reliable CgA values [<a href="#rid57">57</a>]. The utility of measuring CgA levels in patients undergoing radiographic surveillance for detection of recurrence following surgery is debatable, as is its role in the routine follow-up of patients with advanced disease [<a href="#rid58">58</a>]. (See  <a class="medical medical_review" href="/d/html/130551.html" rel="external">"Overview of tumor biomarkers in gastroenteropancreatic neuroendocrine tumors", section on 'Chromogranin A (CgA)'</a>.)</p><p class="headingAnchor" id="H1554580814"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/111962.html" rel="external">"Society guideline links: Well-differentiated gastroenteropancreatic neuroendocrine tumors"</a>.)</p><p class="headingAnchor" id="H46"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span>Neuroendocrine neoplasms arising at different sites within the body are classified according to their histologic features. All commonly used classification systems reflect a basic separation between more indolent, well-differentiated tumors and far more aggressive, high-grade, poorly differentiated neoplasms (neuroendocrine carcinomas) that behave clinically more like small cell lung cancer  (<a class="graphic graphic_table graphicRef122325" href="/d/graphic/122325.html" rel="external">table 1</a>). (See <a class="local">'Classification and nomenclature'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The clinical course of patients with metastatic well-differentiated gastroenteropancreatic neuroendocrine tumors (NETs) is highly variable. Some patients with indolent tumors may remain symptom free for years, even without treatment. Others have symptomatic metastatic disease, either from tumor bulk or peptide hormone hypersecretion, and require therapy. (See <a class="local">'Clinical presentation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Even when advanced, survival times for patients with well-differentiated gastroenteropancreatic NETs are generally better than those for patients with other malignancies, although highly variable. The main prognostic factors are differentiation and grade  (<a class="graphic graphic_table graphicRef122325" href="/d/graphic/122325.html" rel="external">table 1</a>), tumor site  (<a class="graphic graphic_table graphicRef70558" href="/d/graphic/70558.html" rel="external">table 6</a>), disease burden, and the presence of extrahepatic metastases. (See <a class="local">'Prognosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The predominant site of metastatic spread is the liver. Patients in whom metastatic disease is suspected should be evaluated with a triple-phase contrast-enhanced helical computed tomography (CT) or magnetic resonance imaging (MRI) scan to rule out liver metastases. Some clinicians prefer MRI because of its greater sensitivity for liver metastases. (See <a class="local">'Cross-sectional imaging'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Uptake of radiolabeled somatostatin analogs is predictive of a clinical response to therapy with somatostatin analogs and to peptide receptor radionuclide therapy, and it can assist in identifying an otherwise occult primary site. The greater sensitivity of <a class="drug drug_general" data-topicid="108440" href="/d/drug information/108440.html" rel="external">gallium Ga-68 DOTATATE</a>, Ga-68 DOTATOC, or <a class="drug drug_general" data-topicid="129471" href="/d/drug information/129471.html" rel="external">copper Cu-64 DOTATATE</a> positron emission tomography (PET)/CT makes these methods for somatostatin receptor-based imaging preferred over indium-111 (111-In) pentetreotide (OctreoScan) where available. (See <a class="local">'Somatostatin receptor-based imaging techniques'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Changes in biochemical markers may be associated with disease progression and/or response to treatment. Elevated urinary levels of 5-hydroxyindoleacetic acid (5-HIAA) are highly specific for serotonin-producing NETs (ie, those arising in the midgut), although they are not sensitive. (See <a class="local">'Urinary 5-HIAA'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For non-serotonin-producing NETs, serum chromogranin A (CgA) may be more useful than 5-HIAA. However, serum CgA is not specific to NETs and can also be elevated in non-neuroendocrine-related conditions. The utility of measuring CgA levels in patients undergoing radiographic surveillance for detection of recurrence following surgery, and the role of CgA in the follow-up of patients with advanced disease are debatable. (See <a class="local">'Chromogranin A'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">Klimstra DS, Kloppell G, La Rosa S, Rindi G. Classification of neuroendocrine neoplasms of the digestive system. In: WHO Classification of Tumours: Digestive System Tumours, 5th ed, WHO Classification of Tumours Editorial Board (Ed), International Agency for Research on Cancer, Lyon 2019. p.16.</li><li><a class="nounderline abstract_t">Gustafsson BI, Kidd M, Chan A, et al. Bronchopulmonary neuroendocrine tumors. Cancer 2008; 113:5.</a></li><li><a class="nounderline abstract_t">Ter-Minassian M, Chan JA, Hooshmand SM, et al. Clinical presentation, recurrence, and survival in patients with neuroendocrine tumors: results from a prospective institutional database. Endocr Relat Cancer 2013; 20:187.</a></li><li><a class="nounderline abstract_t">Khan MS, Luong TV, Watkins J, et al. A comparison of Ki-67 and mitotic count as prognostic markers for metastatic pancreatic and midgut neuroendocrine neoplasms. Br J Cancer 2013; 108:1838.</a></li><li><a class="nounderline abstract_t">THORSON A, BIORCK G, BJORKMAN G, WALDENSTROM J. Malignant carcinoid of the small intestine with metastases to the liver, valvular disease of the right side of the heart (pulmonary stenosis and tricuspid regurgitation without septal defects), peripheral vasomotor symptoms, bronchoconstriction, and an unusual type of cyanosis; a clinical and pathologic syndrome. Am Heart J 1954; 47:795.</a></li><li><a class="nounderline abstract_t">White BE, Rous B, Chandrakumaran K, et al. Incidence and survival of neuroendocrine neoplasia in England 1995-2018: A retrospective, population-based study. Lancet Reg Health Eur 2022; 23:100510.</a></li><li><a class="nounderline abstract_t">Dasari A, Shen C, Halperin D, et al. Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States. JAMA Oncol 2017; 3:1335.</a></li><li><a class="nounderline abstract_t">Strosberg JR, Cheema A, Weber J, et al. Prognostic validity of a novel American Joint Committee on Cancer Staging Classification for pancreatic neuroendocrine tumors. J Clin Oncol 2011; 29:3044.</a></li><li><a class="nounderline abstract_t">Panzuto F, Nasoni S, Falconi M, et al. Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization. Endocr Relat Cancer 2005; 12:1083.</a></li><li><a class="nounderline abstract_t">Woodard PK, Feldman JM, Paine SS, Baker ME. Midgut carcinoid tumors: CT findings and biochemical profiles. J Comput Assist Tomogr 1995; 19:400.</a></li><li><a class="nounderline abstract_t">Sugimoto E, Lörelius LE, Eriksson B, Oberg K. Midgut carcinoid tumours. CT appearance. Acta Radiol 1995; 36:367.</a></li><li><a class="nounderline abstract_t">Dromain C, de Baere T, Lumbroso J, et al. Detection of liver metastases from endocrine tumors: a prospective comparison of somatostatin receptor scintigraphy, computed tomography, and magnetic resonance imaging. J Clin Oncol 2005; 23:70.</a></li><li><a class="nounderline abstract_t">Sundin A, Vullierme MP, Kaltsas G, et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: radiological examinations. Neuroendocrinology 2009; 90:167.</a></li><li><a class="nounderline abstract_t">Pavel M, Baudin E, Couvelard A, et al. ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology 2012; 95:157.</a></li><li class="breakAll">FDA News Release: FDA approves new diagnostic imaging agent to detect rare neuroendocrine tumors. June 1, 2016. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm504524.htm (Accessed on June 07, 2016).</li><li><a class="nounderline abstract_t">Hope TA, Bergsland EK, Bozkurt MF, et al. Appropriate Use Criteria for Somatostatin Receptor PET Imaging in Neuroendocrine Tumors. J Nucl Med 2018; 59:66.</a></li><li><a class="nounderline abstract_t">Janson ET, Westlin JE, Eriksson B, et al. [111In-DTPA-D-Phe1]octreotide scintigraphy in patients with carcinoid tumours: the predictive value for somatostatin analogue treatment. Eur J Endocrinol 1994; 131:577.</a></li><li><a class="nounderline abstract_t">Kwekkeboom DJ, Krenning EP, Scheidhauer K, et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: somatostatin receptor imaging with (111)In-pentetreotide. Neuroendocrinology 2009; 90:184.</a></li><li><a class="nounderline abstract_t">Ayati N, Lee ST, Zakavi R, et al. Long-Acting Somatostatin Analog Therapy Differentially Alters 68Ga-DOTATATE Uptake in Normal Tissues Compared with Primary Tumors and Metastatic Lesions. J Nucl Med 2018; 59:223.</a></li><li><a class="nounderline abstract_t">Aalbersberg EA, de Wit-van der Veen BJ, Versleijen MWJ, et al. Influence of lanreotide on uptake of 68Ga-DOTATATE in patients with neuroendocrine tumours: a prospective intra-patient evaluation. Eur J Nucl Med Mol Imaging 2019; 46:696.</a></li><li><a class="nounderline abstract_t">Haug AR, Rominger A, Mustafa M, et al. Treatment with octreotide does not reduce tumor uptake of (68)Ga-DOTATATE as measured by PET/CT in patients with neuroendocrine tumors. J Nucl Med 2011; 52:1679.</a></li><li><a class="nounderline abstract_t">Lamberts SW, Bakker WH, Reubi JC, Krenning EP. Somatostatin-receptor imaging in the localization of endocrine tumors. N Engl J Med 1990; 323:1246.</a></li><li><a class="nounderline abstract_t">Kvols LK, Brown ML, O'Connor MK, et al. Evaluation of a radiolabeled somatostatin analog (I-123 octreotide) in the detection and localization of carcinoid and islet cell tumors. Radiology 1993; 187:129.</a></li><li><a class="nounderline abstract_t">Kaltsas G, Korbonits M, Heintz E, et al. Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors. J Clin Endocrinol Metab 2001; 86:895.</a></li><li><a class="nounderline abstract_t">Sadowski SM, Neychev V, Millo C, et al. Prospective Study of 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography for Detecting Gastro-Entero-Pancreatic Neuroendocrine Tumors and Unknown Primary Sites. J Clin Oncol 2016; 34:588.</a></li><li><a class="nounderline abstract_t">Buchmann I, Henze M, Engelbrecht S, et al. Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2007; 34:1617.</a></li><li><a class="nounderline abstract_t">Gabriel M, Decristoforo C, Kendler D, et al. 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med 2007; 48:508.</a></li><li><a class="nounderline abstract_t">Etchebehere EC, de Oliveira Santos A, Gumz B, et al. 68Ga-DOTATATE PET/CT, 99mTc-HYNIC-octreotide SPECT/CT, and whole-body MR imaging in detection of neuroendocrine tumors: a prospective trial. J Nucl Med 2014; 55:1598.</a></li><li><a class="nounderline abstract_t">Santhanam P, Chandramahanti S, Kroiss A, et al. Nuclear imaging of neuroendocrine tumors with unknown primary: why, when and how? Eur J Nucl Med Mol Imaging 2015; 42:1144.</a></li><li><a class="nounderline abstract_t">Nakamoto Y, Sano K, Ishimori T, et al. Additional information gained by positron emission tomography with (68)Ga-DOTATOC for suspected unknown primary or recurrent neuroendocrine tumors. Ann Nucl Med 2015; 29:512.</a></li><li><a class="nounderline abstract_t">Łapińska G, Bryszewska M, Fijołek-Warszewska A, et al. The diagnostic role of 68Ga-DOTATATE PET/CT in the detection of neuroendocrine tumours. Nucl Med Rev Cent East Eur 2011; 14:16.</a></li><li><a class="nounderline abstract_t">Haug AR, Cindea-Drimus R, Auernhammer CJ, et al. The role of 68Ga-DOTATATE PET/CT in suspected neuroendocrine tumors. J Nucl Med 2012; 53:1686.</a></li><li><a class="nounderline abstract_t">Haug AR, Cindea-Drimus R, Auernhammer CJ, et al. Neuroendocrine tumor recurrence: diagnosis with 68Ga-DOTATATE PET/CT. Radiology 2014; 270:517.</a></li><li><a class="nounderline abstract_t">Pfeifer A, Knigge U, Binderup T, et al. 64Cu-DOTATATE PET for Neuroendocrine Tumors: A Prospective Head-to-Head Comparison with 111In-DTPA-Octreotide in 112 Patients. J Nucl Med 2015; 56:847.</a></li><li><a class="nounderline abstract_t">Poeppel TD, Binse I, Petersenn S, et al. 68Ga-DOTATOC versus 68Ga-DOTATATE PET/CT in functional imaging of neuroendocrine tumors. J Nucl Med 2011; 52:1864.</a></li><li class="breakAll">Ga-68 DOTATOC injection. United States Prescribing Information. US National Library of Medicine. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210828s000lbl.pdf (Accessed on September 10, 2019).</li><li><a class="nounderline abstract_t">Johnbeck CB, Knigge U, Loft A, et al. Head-to-Head Comparison of 64Cu-DOTATATE and 68Ga-DOTATOC PET/CT: A Prospective Study of 59 Patients with Neuroendocrine Tumors. J Nucl Med 2017; 58:451.</a></li><li><a class="nounderline abstract_t">Cleary JO, Yeung J, McMeekin H, et al. The significance of incidental brain uptake on 68Ga-DOTATATE PET-CT in neuroendocrine tumour patients. Nucl Med Commun 2016; 37:1197.</a></li><li><a class="nounderline abstract_t">Feldman JM, O'Dorisio TM. Role of neuropeptides and serotonin in the diagnosis of carcinoid tumors. Am J Med 1986; 81:41.</a></li><li><a class="nounderline abstract_t">Meko JB, Norton JA. Management of patients with Zollinger-Ellison syndrome. Annu Rev Med 1995; 46:395.</a></li><li><a class="nounderline abstract_t">Siperstein AE, Berber E. Cryoablation, percutaneous alcohol injection, and radiofrequency ablation for treatment of neuroendocrine liver metastases. World J Surg 2001; 25:693.</a></li><li><a class="nounderline abstract_t">Seregni E, Ferrari L, Bajetta E, et al. Clinical significance of blood chromogranin A measurement in neuroendocrine tumours. Ann Oncol 2001; 12 Suppl 2:S69.</a></li><li><a class="nounderline abstract_t">Tomassetti P, Migliori M, Simoni P, et al. Diagnostic value of plasma chromogranin A in neuroendocrine tumours. Eur J Gastroenterol Hepatol 2001; 13:55.</a></li><li><a class="nounderline abstract_t">Stivanello M, Berruti A, Torta M, et al. Circulating chromogranin A in the assessment of patients with neuroendocrine tumours. A single institution experience. Ann Oncol 2001; 12 Suppl 2:S73.</a></li><li><a class="nounderline abstract_t">Oberg K. Management of neuroendocrine tumours. Ann Oncol 2004; 15 Suppl 4:iv293.</a></li><li><a class="nounderline abstract_t">Campana D, Nori F, Piscitelli L, et al. Chromogranin A: is it a useful marker of neuroendocrine tumors? J Clin Oncol 2007; 25:1967.</a></li><li><a class="nounderline abstract_t">Nehar D, Lombard-Bohas C, Olivieri S, et al. Interest of Chromogranin A for diagnosis and follow-up of endocrine tumours. Clin Endocrinol (Oxf) 2004; 60:644.</a></li><li><a class="nounderline abstract_t">Taupenot L, Harper KL, O'Connor DT. The chromogranin-secretogranin family. N Engl J Med 2003; 348:1134.</a></li><li><a class="nounderline abstract_t">Giovanella L, La Rosa S, Ceriani L, et al. Chromogranin-A as a serum marker for neuroendocrine tumors: comparison with neuron-specific enolase and correlation with immunohistochemical findings. Int J Biol Markers 1999; 14:160.</a></li><li><a class="nounderline abstract_t">Kinney MA, Warner ME, Nagorney DM, et al. Perianaesthetic risks and outcomes of abdominal surgery for metastatic carcinoid tumours. Br J Anaesth 2001; 87:447.</a></li><li><a class="nounderline abstract_t">Veall GR, Peacock JE, Bax ND, Reilly CS. Review of the anaesthetic management of 21 patients undergoing laparotomy for carcinoid syndrome. Br J Anaesth 1994; 72:335.</a></li><li><a class="nounderline abstract_t">Wang YH, Yang QC, Lin Y, et al. Chromogranin A as a marker for diagnosis, treatment, and survival in patients with gastroenteropancreatic neuroendocrine neoplasm. Medicine (Baltimore) 2014; 93:e247.</a></li><li><a class="nounderline abstract_t">Arnold R, Wilke A, Rinke A, et al. Plasma chromogranin A as marker for survival in patients with metastatic endocrine gastroenteropancreatic tumors. Clin Gastroenterol Hepatol 2008; 6:820.</a></li><li><a class="nounderline abstract_t">Korse CM, Taal BG, de Groot CA, et al. Chromogranin-A and N-terminal pro-brain natriuretic peptide: an excellent pair of biomarkers for diagnostics in patients with neuroendocrine tumor. J Clin Oncol 2009; 27:4293.</a></li><li><a class="nounderline abstract_t">Yao JC, Pavel M, Phan AT, et al. Chromogranin A and neuron-specific enolase as prognostic markers in patients with advanced pNET treated with everolimus. J Clin Endocrinol Metab 2011; 96:3741.</a></li><li><a class="nounderline abstract_t">Massironi S, Rossi RE, Casazza G, et al. Chromogranin A in diagnosing and monitoring patients with gastroenteropancreatic neuroendocrine neoplasms: a large series from a single institution. Neuroendocrinology 2014; 100:240.</a></li><li><a class="nounderline abstract_t">Korse CM, Muller M, Taal BG. Discontinuation of proton pump inhibitors during assessment of chromogranin A levels in patients with neuroendocrine tumours. Br J Cancer 2011; 105:1173.</a></li><li><a class="nounderline abstract_t">Strosberg JR, Halfdanarson TR, Bellizzi AM, et al. The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Midgut Neuroendocrine Tumors. Pancreas 2017; 46:707.</a></li></ol></div><div id="topicVersionRevision">Topic 2194 Version 47.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Klimstra DS, Kloppell G, La Rosa S, Rindi G. Classification of neuroendocrine neoplasms of the digestive system. In: WHO Classification of Tumours: Digestive System Tumours, 5th ed, WHO Classification of Tumours Editorial Board (Ed), International Agency for Research on Cancer, Lyon 2019. p.16.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18473355" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Bronchopulmonary neuroendocrine tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23319495" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Clinical presentation, recurrence, and survival in patients with neuroendocrine tumors: results from a prospective institutional database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23579216" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : A comparison of Ki-67 and mitotic count as prognostic markers for metastatic pancreatic and midgut neuroendocrine neoplasms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13158264" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Malignant carcinoid of the small intestine with metastases to the liver, valvular disease of the right side of the heart (pulmonary stenosis and tricuspid regurgitation without septal defects), peripheral vasomotor symptoms, bronchoconstriction, and an unusual type of cyanosis; a clinical and pathologic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36176500" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Incidence and survival of neuroendocrine neoplasia in England 1995-2018: A retrospective, population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28448665" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21709192" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Prognostic validity of a novel American Joint Committee on Cancer Staging Classification for pancreatic neuroendocrine tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16322345" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7540631" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Midgut carcinoid tumors: CT findings and biochemical profiles.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7619613" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Midgut carcinoid tumours. CT appearance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15625361" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Detection of liver metastases from endocrine tumors: a prospective comparison of somatostatin receptor scintigraphy, computed tomography, and magnetic resonance imaging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19077417" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: radiological examinations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22262022" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22262022" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29025982" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Appropriate Use Criteria for Somatostatin Receptor PET Imaging in Neuroendocrine Tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7804439" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : [111In-DTPA-D-Phe1]octreotide scintigraphy in patients with carcinoid tumours: the predictive value for somatostatin analogue treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19713709" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: somatostatin receptor imaging with (111)In-pentetreotide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28729431" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Long-Acting Somatostatin Analog Therapy Differentially Alters 68Ga-DOTATATE Uptake in Normal Tissues Compared with Primary Tumors and Metastatic Lesions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30097670" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Influence of lanreotide on uptake of 68Ga-DOTATATE in patients with neuroendocrine tumours: a prospective intra-patient evaluation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21976529" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Treatment with octreotide does not reduce tumor uptake of (68)Ga-DOTATATE as measured by PET/CT in patients with neuroendocrine tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2170840" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Somatostatin-receptor imaging in the localization of endocrine tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8383865" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Evaluation of a radiolabeled somatostatin analog (I-123 octreotide) in the detection and localization of carcinoid and islet cell tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11158063" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26712231" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Prospective Study of 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography for Detecting Gastro-Entero-Pancreatic Neuroendocrine Tumors and Unknown Primary Sites.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17520251" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17401086" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25168627" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : 68Ga-DOTATATE PET/CT, 99mTc-HYNIC-octreotide SPECT/CT, and whole-body MR imaging in detection of neuroendocrine tumors: a prospective trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25771906" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Nuclear imaging of neuroendocrine tumors with unknown primary: why, when and how?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25894056" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Additional information gained by positron emission tomography with (68)Ga-DOTATOC for suspected unknown primary or recurrent neuroendocrine tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21751167" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : The diagnostic role of 68Ga-DOTATATE PET/CT in the detection of neuroendocrine tumours.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22984220" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : The role of 68Ga-DOTATATE PET/CT in suspected neuroendocrine tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24056402" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Neuroendocrine tumor recurrence: diagnosis with 68Ga-DOTATATE PET/CT.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25952736" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : 64Cu-DOTATATE PET for Neuroendocrine Tumors: A Prospective Head-to-Head Comparison with 111In-DTPA-Octreotide in 112 Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22072704" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : 68Ga-DOTATOC versus 68Ga-DOTATATE PET/CT in functional imaging of neuroendocrine tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22072704" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : 68Ga-DOTATOC versus 68Ga-DOTATATE PET/CT in functional imaging of neuroendocrine tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27660147" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Head-to-Head Comparison of 64Cu-DOTATATE and 68Ga-DOTATOC PET/CT: A Prospective Study of 59 Patients with Neuroendocrine Tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27399848" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : The significance of incidental brain uptake on 68Ga-DOTATATE PET-CT in neuroendocrine tumour patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2432780" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Role of neuropeptides and serotonin in the diagnosis of carcinoid tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7598474" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Management of patients with Zollinger-Ellison syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11376399" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Cryoablation, percutaneous alcohol injection, and radiofrequency ablation for treatment of neuroendocrine liver metastases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11762355" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Clinical significance of blood chromogranin A measurement in neuroendocrine tumours.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11204811" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Diagnostic value of plasma chromogranin A in neuroendocrine tumours.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11762356" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Circulating chromogranin A in the assessment of patients with neuroendocrine tumours. A single institution experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15477324" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Management of neuroendocrine tumours.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17513802" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Chromogranin A: is it a useful marker of neuroendocrine tumors?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15104570" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Interest of Chromogranin A for diagnosis and follow-up of endocrine tumours.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12646671" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : The chromogranin-secretogranin family.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10569138" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Chromogranin-A as a serum marker for neuroendocrine tumors: comparison with neuron-specific enolase and correlation with immunohistochemical findings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11517130" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Perianaesthetic risks and outcomes of abdominal surgery for metastatic carcinoid tumours.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8130054" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Review of the anaesthetic management of 21 patients undergoing laparotomy for carcinoid syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25501094" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Chromogranin A as a marker for diagnosis, treatment, and survival in patients with gastroenteropancreatic neuroendocrine neoplasm.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18547872" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Plasma chromogranin A as marker for survival in patients with metastatic endocrine gastroenteropancreatic tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19667278" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Chromogranin-A and N-terminal pro-brain natriuretic peptide: an excellent pair of biomarkers for diagnostics in patients with neuroendocrine tumor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21994954" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Chromogranin A and neuron-specific enolase as prognostic markers in patients with advanced pNET treated with everolimus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25428270" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Chromogranin A in diagnosing and monitoring patients with gastroenteropancreatic neuroendocrine neoplasms: a large series from a single institution.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21989216" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Discontinuation of proton pump inhibitors during assessment of chromogranin A levels in patients with neuroendocrine tumours.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28609356" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Midgut Neuroendocrine Tumors.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
